IgG protease Mac/IdeS is not essential for phagocyte resistance or mouse virulence of M1T1 group A Streptococcus

mBio

Volumn 4, Issue 4, 2013, Pages

  Okumura, Cheryl Y M ^a,b   Anderson, Ericka L ^a   Döhrmann, Simon ^a   Tran, Dan N ^a   Olson, Joshua ^a   von Pawel Rammingen, Ulrich ^c   Nizet, Victor ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b OCCIDENTAL COLLEGE   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CATHELICIDIN; IMMUNOGLOBULIN G; MAC PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL IMMUNITY; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; CONTROLLED STUDY; GENETIC CODE; HUMAN; HUMAN CELL; INTRACELLULAR KILLING; MAC GENE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROTYPE; STREPTOCOCCUS GROUP A;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS SP. 'GROUP A';

EID: 84883432409     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00499-13     Document Type: Article

References (40)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5:685-694.
2. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470-511.
3. Akesson P, Rasmussen M, Mascini E, von Pawel-Rammingen U, Janulczyk R, Collin M, Olsen A, Mattsson E, Olsson ML, Bjorck L, Christensson B. 2004. Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease. J. Infect. Dis. 189:797-804.
4. Lei B, DeLeo FR, Hoe NP, Graham MR, Mackie SM, Cole RL, Liu M, Hill HR, Low DE, Federle MJ, Scott JR, Musser JM. 2001. Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat. Med. 7:1298-1305.
5. Siegert J, Sastalla I, Chhatwal GS, Medina E. 2006. Vaccination equally enables both genetically susceptible and resistant mice to control infection with group A streptococci. Microbes Infect. 8:347-353.
6. Johansson L, Thulin P, Low DE, Norrby-Teglund A. 2010. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clin. Infect. Dis. 51:58-65.
7. Nordenfelt P, Waldemarson S, Linder A, Mörgelin M, Karlsson C, Malmström J, Björck L. 2012. Antibody orientation at bacterial surfaces is related to invasive infection. J. Exp. Med. 209:2367-2381.
8. Cole JN, Barnett TC, Nizet V, Walker MJ. 2011. Molecular insight into invasive group A streptococcal disease. Nat. Rev. Microbiol. 9:724-736.
9. Kwinn LA, Nizet V. 2007. How group A Streptococcus circumvents host phagocyte defenses. Future Microbiol. 2:75-84.
10. Nizet V. 2007. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J. Allergy Clin. Immunol. 120:13-22.
11. Aziz RK, Kotb M. 2008. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg. Infect. Dis. 14:1511-1517.
12. Maamary PG, Ben Zakour NL, Cole JN, Hollands A, Aziz RK, Barnett TC, Cork AJ, Henningham A, Sanderson-Smith M, Mcarthur JD, Venturini C, Gillen CM, Kirk JK, Johnson DR, Taylor WL, Kaplan EL, Kotb M, Nizet V, Beatson SA, Walker MJ. 2012. Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone. FASEB J. 26:4675-4684.
13. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. 2006. Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2:e5. doi:10.1371/journal.ppat.0020005.
14. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, McArthur JD, Dinkla K, Aziz RK, Kansal RG, Simpson AJ, Buchanan JT, Chhatwal GS, Kotb M, Nizet V. 2007. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat. Med. 13:981-985.
15. Aziz RK, Pabst MJ, Jeng A, Kansal R, Low DE, Nizet V, Kotb M. 2004. Invasive M1T1 group A streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol. Microbiol. 51:123-134.
16. Cole JN, Pence MA, von Kockritz-Blickwede M, Hollands A, Gallo RL, Walker MJ, Nizet V. 2010. M protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A Streptococcus. mBio 1:e00191-10. doi:10.1128/ mBio.00191-10.
17. von Pawel-Rammingen U, Johansson BP, Björck L. 2002. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21:1607-1615.
18. Agniswamy J, Nagiec MJ, Liu M, Schuck P, Musser JM, Sun PD. 2006. Crystal structure of group A Streptococcus Mac-1: insight into dimermediated specificity for recognition of human IgG. Structure 14:225-235.
19. Lei B, DeLeo FR, Reid SD, Voyich JM, Magoun L, Liu M, Braughton KR, Ricklefs S, Hoe NP, Cole RL, Leong JM, Musser JM. 2002. Opsonophagocytosis-inhibiting Mac protein of group a Streptococcus: identification and characteristics of two genetic complexes. Infect. Immun. 70:6880-6890.
20. Vindebro R, Spoerry C, von Pawel-Rammingen U. 2013. Rapid IgG heavy chain cleavage by the streptococcal IgG endopeptidase IdeS is mediated by IdeS monomers and is not due to enzyme dimerization. FEBS Lett. 587:1818-1822.
21. von Pawel-Rammingen U. 2012. Streptococcal IdeS and its impact on immune response and inflammation. J. Innate Immun. 4:132-140.
22. Söderberg JJ, von Pawel-Rammingen U. 2008. The streptococcal protease IdeS modulates bacterial IgGFc binding and generates 1/2Fc fragments with the ability to prime polymorphonuclear leucocytes. Mol. Immunol. 45:3347-3353.
23. Collin M, Olsén A. 2001. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect. Immun. 69:7187-7189.
24. Collin M, Olsén A. 2001. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J. 20:3046-3055.
25. Persson H, Vindebro R, von Pawel-Rammingen U. 2013. The streptococcal cysteine protease SpeB is not a natural immunoglobulin cleaving enzyme. Infect. Immun. 81:2236-2241.
26. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, Feramisco J, Nizet V. 2006. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16:396-400.
27. Pence MA, Rooijakkers SH, Cogen AL, Cole JN, Hollands A, Gallo RL, Nizet V. 2010. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus. J. Innate Immun. 2:587-595.
28. Sjögren J, Okumura CY, Collin M, Nizet V, Hollands A. 2011. Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence. BMC Microbiol. 11:120. doi:10.1186/1471-2180-11-120.
29. Nandakumar KS, Johansson BP, Björck L, Holmdahl R. 2007. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 56:3253-3260.
30. Lauth X, von Köckritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall B, Ghosh P, Gallo RL, Nizet V. 2009. M1 protein allows group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. J. Innate Immun. 1:202-214.
31. Timmer AM, Timmer JC, Pence MA, Hsu LC, Ghochani M, Frey TG, Karin M, Salvesen GS, Nizet V. 2009. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J. Biol. Chem. 284:862-871.
32. Datta V, Myskowski SM, Kwinn LA, Chiem DN, Varki N, Kansal RG, Kotb M, Nizet V. 2005. Mutational analysis of the group A streptococcal operon encoding streptolysin S and its virulence role in invasive infection. Mol. Microbiol. 56:681-695.
33. Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, Mishalian I, Sriskandan S, Hanski E, Nizet V. 2008. The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe 4:170-178.
34. Söderberg JJ, Engström P, von Pawel-Rammingen U. 2008. The intrinsic immunoglobulin G endopeptidase activity of streptococcal Mac-2 proteins implies a unique role for the enzymatically impaired Mac-2 protein of M28 serotype strains. Infect. Immun. 76:2183-2188.
35. Okumura CY, Hollands A, Tran DN, Olson J, Dahesh S, von Köckritz-Blickwede M, Thienphrapa W, Corle C, Jeung SN, Kotsakis A, Shalwitz RA, Johnson RS, Nizet V. 2012. A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J. Mol. Med. 90:1079-1089.
36. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, McGeer A, Kotb M. 2000. Genetic relatedness and superantigen expression in group A Streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect. Immun. 68:3523-3534.
37. Jeng A, Sakota V, Li Z, Datta V, Beall B, Nizet V. 2003. Molecular genetic analysis of a group A Streptococcus operon encoding serum opacity factor and a novel fibronectin-binding protein, SfbX. J. Bacteriol. 185: 1208-1217.
38. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. 2007. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm. Res. 56:45-50.
39. von Köckritz-Blickwede M, Chow OA, Nizet V. 2009. Fetal calf serum contains heat-stable nucleases that degrade neutrophil extracellular traps. Blood 114:5245-5246.
40. Chow OA, von Köckritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, Nizet V. 2010. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8:445-454.